TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: REMUS · data 2026-11-02
Remus Pharmaceuticals Ltd.
In plain words
Price: 16.0% below its 52-week high of ₹1,039.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹854 cr |
| Net profit (last 12 months) | ₹37 cr |
| Sales growth, 3 years (yearly) | 166.6% |
| Profit growth, 3 years (yearly) | 63.2% |
At a glance
P/E 27.8, P/B 2.9, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 12.2%, ROCE 14.7%, operating margin 6.3%: how much profit it earns on the money it uses.
Debt/equity 0.08, Profit growth 63.2% and sales growth 166.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Profit grew 63.2% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Remus Pharmaceuticals Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.08, which is very low.
What is Remus Pharmaceuticals Ltd.'s P/E ratio?
About 27.8, based on the last 12 months' earnings and a price of ₹872.95 (data 2026-11-02).
What is the 52-week high and low of Remus Pharmaceuticals Ltd.?
The 52-week high is ₹1,039 and the 52-week low is ₹580.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Remus Pharmaceuticals Ltd. | ₹872.95 | ₹994 cr | 27.8 | 2.9 | 12.2% | 14.7% | 0.08 | +28.7% |
| Bafna Pharmaceuticals Limited | ₹447.9 | ₹1,060 cr | 136.1 | — | 12.3% | 9.2% | 0.39 | +218.1% |
| Bajaj Healthcare Ltd | ₹308.3 | ₹1,031 cr | 51.8 | 1.9 | 4.3% | 13.2% | 0.47 | -36.6% |
| Sigachi Industries Limited | ₹25.84 | ₹1,009 cr | 38.9 | — | -14.6% | 6.1% | 0.31 | -30.0% |
| Lincoln Pharmaceuticals Ltd | ₹506.15 | ₹1,005 cr | 10.5 | — | 12.3% | 10.9% | 0.01 | -4.9% |
| Sudarshan Pharma Industries Ltd | ₹35.7 | ₹895 cr | 30.5 | 4.7 | 16.3% | 28.8% | 1.84 | +5.6% |
Compare REMUS with BAFNAPH in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open REMUS in TickerKhoj →